Takeda looks to build vaccines business

Share this article:
Takeda is getting into vaccines with the launch of a dedicated global division that will make use of Nycomed A/S's business infrastructure in Europe and emerging markets.

The initial focus of the Tokyo-based business will be on Asian markets where Takeda has local sales subsidiaries, including China and India, and it will make use of the company's R&D operations in Osaka and Hikari, but “all other operations will be established in Chicago, in anticipation of global development of the vaccine business,” said Takeda spokesman Hisashi Tokinoya. That includes planning and coordination, responsible for mapping mid- and long-term strategy for the unit, and business development, charged with plotting opportunities for global expansion and alliances. The unit will launch with 70 employees, mostly Japan-based vaccine specialists working on R&D.

The new division will be headed by Dr. Rajeev Venkayya, who joins the firm from the Bill & Melinda Gates Foundation, where he was director of vaccine delivery in the Global Health Program, overseeing the foundation's polio eradication efforts and investment in the Global Alliance for Vaccines and Immunization. He was previously special assistant to the president for biodefense at the White House, in which capacity he headed development and implementation of the National Strategy for Pandemic Influenza.

The company has manufactured pediatric vaccines for six decades and is currently working on vaccines for HPV, Haemophilius Influenzae type b (Hib) and polio. Takeda is also “expediting preparations for production and supply” of pandemic flu vaccines.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...